Osteoporosis is a condition in which the bone matrix is compromised, leading to thin, fragile bones that fracture easily. It has a significant socio-economic impact, both from the cost of treating such fractures and for the individual going through what is often a traumatic experience with a lengthy recovery. Therefore, as clinicians our focus should be on the early identification of disease and instigation of treatment. This article focuses on the diagnosis and management of osteoporosis, summarizing current guidance along with providing practical tips on how to manage affected patients in our consultation rooms.
Get full access to this article
View all access options for this article.
References
1.
AbrahamsenBEikenPEastellR. (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. Journal of Bone and Mineral Research24 (6):1095–1102. doi:10.1359/jbmr.081247.
2.
BlackDMDelmasPDEastellERReidIRBoonenSCauleyJACummingsSR (2007) Once Yearly Zoledronic Acid of Treatment of Postmenopausal women (HORIZON). New England Journal of Medicine. 356:1809–1822. Retrieved from: www.nejm.org/doi/full/10.1056/NEJMoa067312#t=article.
3.
BollandMJAvenellABaronJAGreyAMacLennenGSGambleGDReidIR (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. British Medical Journal. 341: c3691. doi:10.1136/bmj.c3691.
4.
British National Formulary 61. (2011). BMJ group and Pharmaceutical Press, UK.
5.
CollinsGSMallettSAltmanDG. (2011) Predicting risk of osteoporotic and hip fracture in the United Kingdom: Prospective independent and external validation of QFractureScores. British Medical Journal. 342: d3651. doi:10.1136/bmj.d3651.
Hippisley-CoxJCouplandC. (2009). Predicting risk of osteoporotic fracture in men and women in England and Wales; prospective derivation and validation of QFractureScores. British Medical Journal. 339: b4229. doi:10.1136/bmj.b4229.
9.
HodsmanABBauerDCDempsterDDianLHanleyDAHarrisSTYuenCK (2005). Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocrinology Review. 26: 688–703. Retrieved from: http://edrv.endojournals.org/content/early/2005/03/15/er.2004–0006.full.pdf.
10.
HyppönenEPowerC. (2007). Hypovitaminosis D in British adults age 45y; nationwide cohort study of dietary and lifestyle predictor. American Journal of Clinical Nutrition. 85: 860–868. Retrieved from: www.ajcn.org/content/85/3/860.full.pdf+html.
11.
KlippelJHStoneJHCroffordLJWhitePH. (2008). Primer on the rheumatic diseases. Springer Science and Business Media, New York.
12.
LoJCPressmanAROmarMAEttingerB. (2006). Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis International. 17:922–928. doi:10.1007/s00198-006-0085-2.
NICE. (updated 2011a). Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Retrieved from: www.nice.org.uk/nicemedia/live/11746/47176/47176.pdf.
15.
NICE. (updated 2011b). Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Retrieved from: www.nice.org.uk/nicemedia/live/11748/42447/42447.pdf.
National Osteoporosis Guideline Group (NOGG) (2010b). Osteoporosis. Clinical guideline for prevention and treatment. Executive Summary. Retrieved from: www.shef.ac.uk/NOGG/NOGG_Executive_Summary.pdf.
Park-WyllieLYMamdaniMMJuurlinkDNHawkerGAGunrajNAustinPCLaupacisA (2011). Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. The Journal of the American Medical Association. 305 (8):783. doi:10.1001/jama.2011.190.
23.
PearceSHSCheethamTD. (2010). Diagnosis and management of vitamin D deficiency. British Medical Journal. 340: 142–147. doi:10.1136/bmj.b5664.
SIGN. (2003). Management of Osteoporosis. A national clinical guideline. Retrieved from: www.sign.ac.uk/pdf/sign71.pdf.
29.
World Health Organization. (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Report Series, No. 843.
